Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID-LV305 in NY-ESO-1 Positive Advanced Cancer
NCT02122861Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2014
- Primary completion
- Nov 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of LV305 in melanoma, sarcoma, ovarian cancer and 1 more (2 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability up to 5 years. Started May 2014; status: completed.
02
Drugs
LV305
03
Conditions
melanomasarcomaovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02122861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122861.